Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567710 · ClinicalTrials.gov registry record · Phase 2
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
A Phase 2 study, sponsored by BioLineRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT00567710: Completed Phase 2 study, sponsored by BioLineRx.
NCT00567710 is a Phase 2 study that has completed, run by BioLineRx. The registered enrollment target is 360 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567710, a Phase 2 study, has completed, sponsored by BioLineRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG BL - 1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567710
The ClinicalTrials.gov registry entry for NCT00567710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioLineRx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00567710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00567710 about?
NCT00567710 is a clinical study titled "A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study". This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.
What is the current status of trial NCT00567710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2008-07. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00567710?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), BL - 1020 (DRUG).
Who is sponsoring clinical trial NCT00567710?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.